IDH1 and acute myeloid leukemia: In patients SU360 (SF3B1 and KMT2D mutant secondary AML), SU484 (IDH1/FLT3-ITD/NPM1 mutant), and SU892 (RUNX1-mutant/FLT3-TKD), there were substantial epigenetic differences between diagnosis and relapse, along with significant heterogeneity within each timepoint (Figure 4c and d, Figure 4—figure supplement 1a).